Analyst Insight Series
Decision Resources' analysts are the leading experts on various healthcare issues, from specific drug market analysis to insights on industry trends.
Listen to a brief interview with analyst Kathryn Benton in which she discusses the drug treatment market for Crohn's disease. Ms. Benton is the author of the recent Pharmacor report Crohn's Disease which finds that the market for the disease will more than double, from $1.5 billion in 2006 to $4 billion in 2016, in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Read more and listen to audio clip
Listen to a brief interview with analyst Kaitlyn Sullivan in which she discusses the drug treatment market for community-acquired pneumonia. Ms. Sullivan is the author of the recent Pharmacor report Community Acquired Pneumonia, which finds that the most promising antibiotics in development for the treatment of community-acquired pneumonia are intravenous agents that will be used in the hospital setting, including Johnson & Johnson/Basilea’s ceftobiprole and Forest’s ceftaroline. Read more and listen to audio clip
Listen to a brief interview with analyst Victor Li, Ph.D., in which he discusses the drug treatment market for liver cancer in China. Dr. Li is the author of the recent Emerging Markets report entitled Liver Cancer in China which forecasts that the Chinese hepatocellular carcinoma (HCC; the most prevalent type of primary liver cancer) market will quadruple between 2006 and 2011. Read more and listen to audio clip
Listen to a brief interview with Irene Koulinska, M.D., in which she discusses the drug treatment market for psoriasis. Dr. Koulinska is the author of the Pharmacor report entitled Psoriasis which finds that Amgen/Wyeth/Takeda's Enbrel will sustain its first-to-market advantage over other biologics and continue to dominate the psoriasis market through 2011. However, Abbott/Eisai's Humira will challenge Enbrel's leading position and reach more than $1 billion in sales by 2016.
Read more and listen to audio clip
Listen to a brief interview with Cindy Mundy, Ph.D., in which she discusses the drug treatment market for urge urinary incontinence. Dr. Mundy is an author of the Pharmacor report entitled Urge Urinary Incontinence which finds that, although novel therapies will contribute to sales growth, anticholinergics, including Pfizer/Schwarz Pharma's Toviaz, will continue to dominate the urge urinary incontinence drug market over the next decade.
Listen to a brief interview with analyst Carlos Dedesma, Ph.D., in which he discusses the drug treatment market for bipolar disorder. Dr. Dedesma is the author of the recent Pharmacor report Bipolar Disorder, which finds that the use of the AstraZeneca's Seroquel XR and Solvay/Lundbeck/Wyeth's bifeprunox will help offset a decrease in the overall bipolar disorder market over the next decade. Read more and listen to audio clip
Listen to a brief interview with analyst Mary Argent-Katwala, Ph.D., in which she discusses the drug treatment market for peripheral arterial disease. Dr. Argent-Katwala is the author of the Pharmacor report entitled Peripheral Arterial Disease which finds that the market entry of novel angiogenic agents, including a future blockbuster drug from Genzyme, could revolutionize symptomatic treatment of peripheral arterial disease.
Listen to a brief interview with analyst Vickie Lai in which she discusses the drug treatment market for Asthma in China. Ms. Lai is the author of the Emerging Markets-China report Asthma in China which forecasts that, owing to an expanding prevalent population, the diagnosed asthma population in China will increase 57 percent in the next five years.
Listen to a brief interview with analyst Greg Dwyer in which he discusses the drug treatment market for benign prostatic hyperplasia. Mr. Dwyer is the author of the recent Pharmacor report Benign Prostatic Hyperplasia, which finds that the patent expiries of Proscar and Flomax/Harnal will cause a significant decline in near-term sales of therapies to treat the disease. Read more and listen to audio clip
Listen to a brief interview with analyst Marcus Hoyle in which he discusses the drug treatment market for colorectal cancer. Mr. Hoyle is the author of the Pharmacor report Colorectal Cancer which finds that increasing use of Avastin and Erbitux as well as modest uptake of Vectibix will help to counter the loss of sales caused by the generics erosion of Eloxatin.
Listen to a brief interview with analyst Nitasha Manchanda, Ph.D., in which she discusses the drug treatment market for alzheimer's disease. Dr. Manchanda is the author of the recent Pharmacor report Alzheimer's Disease, which finds that Elan/Wyeth's bapineuzumab will drive the alzheimer's disease drug market to more than triple by 2016, reaching $8.8 billion. Read more and listen to audio clip
Listen to a brief interview with director John Lebbos, M.D. in which he discusses the HIV drug treatment market. Dr. Lebbos is an author of the Pharmacor report Emerging HIV Therapies which finds that continued uptake of new drugs, including Atripla and Prezista, and the launch of several novel agents, such as maraviroc, will drive near-term expansion of the HIV drug market.
Listen to a brief interview with analyst Jonathan Searles in which he discusses the drug treatment market for acute ischemic stroke. Mr. Searles is the author of the recent Pharmacor report Acute Ischemic Stroke, which finds that for more than a decade the acute ischemic stroke market has been a virtual “graveyard” for drug development as only one therapy, Genentech’s Activase, has been approved in all major markets. Read more and listen to audio clip
Listen to a brief interview with analyst Dancella Fernandes, Ph.D., in which she discusses the drug treatment market for rheumatoid arthritis. Dr. Fernandes is the author of the recent Pharmacor report Emerging Rheumatoid Arthritis Therapies, which finds that novel biologic agents from UCB, Centocor/Schering-Plough/Tanabe/Janssen, and Roche/Chugai will play significant roles in ushering in a new phase of growth in the rheumatoid arthritis drug market. Read more and listen to audio clip
Listen to a brief interview with analyst Nikhil Mehta in which he discusses the drug treatment market for Dyslipidemia. Nikhil is the author of the Pharmacor report entitled Dyslipidemia which finds that novel agents that can significantly reduce low-density lipoprotein (LDL) beyond the reduction already achieved by a statin will have a vital role in the future treatment of dyslipidemia.
Listen to a brief interview with analyst Joanna Kim in which she discusses the drug treatment market for psoriatic arthritis. Ms. Kim is the author of the recent Pharmacor report Psoriatic Arthritis, which finds that the emergence of high-priced biologic agents has dramatically transformed the drug market for treating psoriatic arthritis. Read more and listen to audio clip
Listen to a brief interview with analyst Jeremy Goldman, M.D., in which he discusses the drug treatment market for hypertension. Dr. Goldman is the author of the recent Pharmacor report Hypertension, which finds that new drugs from Novartis and Daiichi Sankyo will achieve blockbuster status in the drug market to treat hypertension. Read more and listen to audio clip
Listen to a brief interview with analyst Donny Wong, Ph.D., in which he discusses the drug treatment market for metabolic syndrome. Dr. Wong is the author of the recent Pharmacor report Metabolic Syndrome, which finds that emerging agents from Metabolex/Johnson & Johnson, Merck, Novartis, and Amylin/Eli Lilly are among the most promising drugs in development for metabolic syndrome. Read more and listen to audio clip
Listen to a brief interview with analyst Bethany Kiernan, Ph.D., in which she discusses the drug treatment market for multiple sclerosis. Dr. Kiernan is the author of the Pharmacor report Multiple Sclerosis 2005 - 2020 which finds that emerging oral therapies for multiple sclerosis, including a new drug from Novartis/Mitsubishi Pharma, will capture 25% of the market share by 2020.
The Analyst Insight Series from Decision Resources features audio and written presentations from MDs and PhDs with experience in the health care industry. With topics including healthcare market analysis, pharmaceutical treatments, and new regimens for disease, we offer an educational and informative way to stay up to date on new trends in the treatment market.
Decision Resources helps people in the Pharma and medical fields find new markets, discover emerging trends, and offer diverse treatment options to patients worldwide. Given the wide variety of medical care conditions and regulations around the world, it is essential for anyone in the drug marketing field to know all the trends in healthcare market analysis. Furthermore, the doctors who present information also can give firsthand accounts of the cultural and social barriers that may need to be overcome in order to give the best possible treatment. Audio interviews with healthcare professionals and marketing experts make it possible for anyone in the industry to get an overview of the challenges faced in today's pharmaceutical industry. Additionally, new trends and therapies for HIV, Multiple Sclerosis, Drug Resistant TB, and cancer are discussed by doctors who work in every phase of the business from testing to treatment.
